AstraZeneca’s Fasenra Receives NMPA’s Approval to Treat Severe Eosinophilic Asthma
Shots:
- The approval was based on a P-III (MIRACLE) study that assessed the safety & efficacy of Fasenra (benralizumab) as maintenance therapy for severe eosinophilic asthma adults (n=695; age≥12). Currently approved in >80 countries globally (incl. US & EU)
- Fasenra (30mg, SC, Q8W) achieved all 1EPs and key 2EPs vs PBO that shows reduced in AAER over 48 wks by 74% (0.49 vs 1.88) & 2EPs changed at 48wks in pre-bronchodilator FEV1 and TASS. Safety and tolerability were consistent with the known safety profile
- Fasenra is being assessed in other indications such as COPD, CRSwNP, EGPA & hypereosinophilic syndrome. Fasenra is an in-license from BioWa (a subsidiary of Kyowa Kirin) and developed by AstraZeneca
Ref: AstraZeneca | Image: AstraZeneca
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies. He can be contacted at connect@pharmashots.com
